The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1- naphthylaldehyde benzoyl hydrazone

Blood

Volumn 89, Issue 8, 1997, Pages 3025-3038

  Richardson, D R ^a   Milnes, K ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE 2 THIOPHENECARBOXYLHYDRAZONE; 2 HYDROXY 1 NAPHTHYLALDEHYDE 4 CHLOROBENZOYLHYDRAZONE; 2 HYDROXY 1 NAPHTHYLALDEHYDE 4 FLUOROBENZOYLHYRAZONE; 2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CHELATING AGENT; DEFEROXAMINE; FERRITIN; IRON; PYRIDOXAL ISONICOTINOYLHYDRAZONE; SALICYLALDEHYDE 3 TERT BUTYLBENZOYLHYDRAZONE; TRANSFERRIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; ETIOLOGY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRON CHELATION; IRON METABOLISM; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SYNTHESIS;

EID: 0030894798     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.8.3025     Document Type: Article

References (46)

1. Modell B, Berdoukas V: The Clinical Approach to Thalassemia. New York, NY, Grune & Stratton, 1984
2. Hoffbrand AV, Ganeshaguru K, Hooton JWL, Tatersall MHN: Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 33:517, 1976
3. Estrov Z, Tawa A, Wang X-H, Dube ID, Sulh H, Cohen A, Gelfand EW, Freedman MH: In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood 69:757, 1987
4. Becton DL, Roberts B: Antileukemic effects of desferrioxamine on human myeloid leukemia cell lines. Cancer Res 49:4809, 1989
5. Kemp JD, Thorson JA, Stewart BC, Naumann PW: Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: Evidence for a threshold model of iron deprivation toxicity. Cancer Res 52:4144, 1992
6. Richardson D, Ponka P, Baker E: The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 54:685, 1994
7. Blatt J, Stitely S: Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res 47:1749, 1987
8. Becton DL, Bryles P: Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 48:7189, 1988
9. Skala JP, Rogers PCJ, Chan K-W, Chao HY, Rodriguez WC: Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma, in Advances in Bone Marrow Purging and Processing, New York, NY, Wiley-Liss, 1992, p 71
10. Helson C, Helson L: Deferoxamine and human neuroblastoma and primitive neuroectodermal tumor cell lines. Anticancer Res 12:481, 1992
11. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L: Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50:4929, 1990
12. Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, Fidani P, Amici A, Helson L: Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 15:319, 1992
13. Ponka P, Borova J, Neuwirt J, Fuchs O: Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97:317, 1979
14. Hoy T, Humphreys J, Jacobs A, Williams A, Ponka P: Effective iron chelation following oral adminstration of an isoniazid pyridoxal hydrazone. Br J Haematol 43:443, 1979
15. Ponka P, Richardson D, Baker E, Schulman HM, Edward JT: Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta 967:122, 1988
16. Baker E, Richardson DR, Gross S, Ponka P: Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15:492, 1992
17. Richardson DR, Ponka P: The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 124:660, 1994
18. Richardson DR, Tran E, Ponka P: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295, 1995
19. Johnson DK, Murphy TB, Rose NJ, Goodwin WH, Pickart L: Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone. Inorg Chim Acta 67:159, 1982
20. Richardson DR, Baker E: The uptake of iron and transferrin by the human melanoma cell. Biochim Biophys Acta 1053:1, 1990
21. Seligman PA, Schleicher RB, Siriwardana G, Domenico J, Gelfand EW: Effects of agents that inhibit cellular iron incorporation on bladder cell proliferation. Blood 82:1608, 1993
22. Richardson DR, Ponka P, Vyoral D: Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism. Blood 87:3477, 1996
23. Boshell M, McLeod J, Walker L, Hall N, Patel Y, Sansom D: Effects of antigen presentation on superantigen-induced apoptosis mediated by Fas/Fas ligand interactions in human T cells. Immunology 87:586, 1996
24. Hileti D, Panayiotidis P, Hoffbrand AV: Iron chelators induce apoptosis in proliferating cells. Br J Haematol 89:181, 1995
25. Panayiotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV: Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukemia cells in vitro. Br J Haematol 85:439, 1993
26. Offen D, Ziv I, Gorodin S, Barzilai A, Malik Z, Melamed E: Dopamine-induced programmed cell death in mouse thymocytes. Biochim Biophys Acta 1268:171, 1995
27. Richardson DR, Dickson L, Baker E: Intermediate steps in cellular iron uptake from transferrin. II. A cytoplasmic pool of iron is released from cells by temperature-dependent mechanical wounding. In Vitro 32:486, 1996
28. Ul-Haq R, Wereley JP, Chitambar CR: Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol 23:428, 1995
29. Kerr JFR, Wyllie AH, Currie AR: in Potten CS (ed): Perspectives on Mammalian Cell Death. Oxford, UK, Oxford, 1972, p 66
30. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251, 1980
31. Arends MJ, Morris RG, Wyllie AH: Apoptosis. The role of the endonuclease. Am J Pathol 136:593, 1990
32. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555, 1980
33. Duke RC, Chervenak R, Cohen JJ: Endogenous endonuclease-induced DNA fragmentation: An early event in cell-mediated cytolysis. Proc Natl Acad Sci USA 80:6361, 1983
34. Summers MR, Jacobs A, Tudway D, Perera P, Ricketts C: Studies of desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42:547, 1979
35. Ueda N, Shah SV: Apoptosis. J Lab Clin Med 124:169, 1994
36. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Gräslund A, Thelander L: Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 268:26200, 1993
37. 1 phase of the cell cycle. Cancer Res 53:3968, 1993
38. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC: Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cells in culture. Blood 77:2049, 1991
39. Chresta CM, Masters JRW, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56:1834, 1996
40. Bergeron RJ, Ingeno MJ: Microbial iron chelator-induced cell cycle synchronisation in L1210 cells: Potential in combination chemotherapy. Cancer Res 47:6010, 1987
41. Blatt J, Taylor SR, Kontoghiorghes GJ: Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res 44:2925, 1989
42. Bomford A, Isaac J, Roberts S, Edwards A, Young S, Williams R: The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukemic cells. Biochem J 226:243, 1986
43. Renton FJ, Jeitner TM: Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem Pharmacol 51:1553, 1996
44. Sharpe HBA, Field EO, Hellman K: Mode of action of the cytostatic agent "ICRF 159". Nature 226:524, 1970
45. Brittenham GM: Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration. Semin Hematol 27:112, 1990
46. Richardson DR, Wis Vitolo L, Baker E, Webb J: Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry. Biol Metals 2:69, 1989